Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.63 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.63 |
| ▸ | ACHE | P22303 | 12/20 | 0.42 |
| ▸ | TSHR | P16473 | 1/20 | 0.39 |
| ▸ | FAAH | O00519 | 2/20 | 0.39 |
| ▸ | MEN1 | O00255 | 1/20 | 0.38 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.38 |
| ▸ | CASP2 | P42575 | 1/20 | 0.36 |
| ▸ | LMNA | P02545 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL28340776 | 1.00 | ALDH1A1 (0.63) | ALDH1A1SMN1; SMN2ACHETSHRFAAH | |
| SCHEMBL29991209 | 1.00 | ALDH1A1 (0.63) | ALDH1A1SMN1; SMN2ACHETSHRFAAH | |
| SCHEMBL28655610 | 0.98 | ALDH1A1 (0.59) | ALDH1A1SMN1; SMN2ACHETSHRFAAH | |
| SCHEMBL25286745 | 0.92 | ALDH1A1 (0.56) | ALDH1A1SMN1; SMN2ACHETSHRMEN1 | |
| SCHEMBL31050436 | 0.85 | ALDH1A1 (0.42) | ALDH1A1SMN1; SMN2ACHEFAAHMEN1 | |
| SCHEMBL28343261 | 0.84 | ALDH1A1 (0.47) | ALDH1A1SMN1; SMN2ACHETSHRLMNA | |
| SCHEMBL25282552 | 0.84 | ALDH1A1 (0.48) | ALDH1A1SMN1; SMN2TSHRLMNA | |
| SCHEMBL28531200 | 0.84 | HDAC3 (0.42) | ALDH1A1SMN1; SMN2ACHEFAAHMEN1 | |
| SCHEMBL28099785 | 0.81 | HDAC3 (0.40) | ALDH1A1SMN1; SMN2ACHETSHRFAAH | |
| SCHEMBL18920948 | 0.81 | FAAH (0.57) | ALDH1A1SMN1; SMN2ACHETSHRFAAH |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-112574089-B | Photo-induced multifunctional crosslinking agent, preparation method and application thereof | 中国科学院上海药物研究所 | 2023-09-05 | — | — | CN | disclosed |
| CN-108350062-B | Targeted protein degradation to attenuate adverse inflammatory responses associated with adoptive T cell therapy | 达纳-法伯癌症研究所股份有限公司 | 2022-10-14 | — | — | CN | disclosed |
| CN-113677668-A | Bifunctional compounds and methods for androgen receptor targeted ubiquitination | 蒙特利诺治疗公司 | 2021-11-19 | — | — | CN | disclosed |
| US-20210292298-A1 | BI-FUNCTIONAL COMPOUNDS AND METHODS FOR TARGETED UBIQUITINATION OF ANDROGEN RECEPTOR | DBD THERAPEUTICS, LLC | 2021-09-23 | — | — | US | disclosed |
| CN-112574089-A | Photoinduced multifunctional cross-linking agent, and preparation method and application thereof | 中国科学院上海药物研究所 | 2021-03-30 | — | — | CN | disclosed |
| CN-111386263-A | Modulation of chimeric antigen receptors | 达纳-法伯癌症研究所有限公司 | 2020-07-07 | — | — | CN | disclosed |
| CN-107257800-B | Method for inducing target protein degradation by bifunctional molecules | 达纳-法伯癌症研究所股份有限公司 | 2020-06-30 | — | — | CN | disclosed |
| CN-110621322-A | Modulatable endogenous protein degradation with heterobifunctional compounds | 达纳-法伯癌症研究所有限公司 | 2019-12-27 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210292298-A1 | BI-FUNCTIONAL COMPOUNDS AND METHODS FOR TARGETED UBIQUITINATION OF ANDROGEN RECEPTOR | AR, ADRM1, PSMA3 | ALDH1A1 2547/4885SMN1; SMN2 4554/4885ACHE 3642/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.